- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00006156
Feasibility Study for Development of an Early Test for Ovarian Failure
FSH-Stimulated Inhibin B as a Marker for Early Ovarian Insufficiency
This purpose of this study is to gain information about normal ovarian function that will be useful in developing a test for early detection of ovarian failure. The ovaries produce female hormones, such as estrogen, that are important in maintaining a woman's health. When the ovaries do not work properly, problems can develop. Unfortunately, there is no test that can detect ovarian failure early in its course. By the time premature ovarian failure is diagnosed in young women, two-thirds have already developed osteopenia (loss of some bone mass) and nearly one in ten have osteoporosis, a greater loss of bone mineral density that weakens bones and increases the risk of fractures.
Women with normal ovarian function ages 18 to 55 and postmenopausal women 60 years of age or older may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood tests and vaginal ultrasound examination. For the ultrasound study, a probe that emits sound waves is inserted into the vagina, and the sound waves are converted to form images of the ovaries. The procedure is done with an empty bladder and takes about 10 minutes. After this screening visit (Visit 1), those enrolled in the study will return to the NIH Clinical Center for the following additional procedures:
Visit 2-Will be scheduled between days 3 and 5 of the menstrual cycle (for women who are still menstruating). Participants will have blood tests to measure hormone levels and to check for pregnancy, and will have another transvaginal ultrasound examination. They will then receive an injection of a synthetic form of follicle stimulating hormone (FSH), a hormone the body makes normally.
Visits 3 and 4-Will be scheduled 24 and 36 hours after the FSH injection given during Visit 2 for collection of blood samples.
Visit 5-Will be scheduled 48 hours after the FSH injection for additional blood sampling and a final transvaginal ultrasound examination.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
- INCLUSION CRITERIA:
A. Women with normal ovarian function:
Age 18 to 55.
Normal body mass index (18-30 kg/m(2)).
Normal menstrual cycles (between 25-35 days in length).
Ovulatory serum progesterone concentrations (in excess of 6 ng/mL in the menstrual cycle just preceding the study cycle).
B. Postmenopausal women (to serve as negative controls):
Greater than or equal to 60 years of age.
Proven fertility (as evidenced by a history of pregnancy regardless of outcome).
Normal body mass index (18-30 kg/m(2)).
Naturally menopausal: amenorrhea for at least one year; serum FSH greater than 40 IU/mL.
C. Women carriers of FMR1 premutations:
Age 18 to 40.
50 to 200 CGG repeats.
Normal menstrual cycles (between 25-35 days in length).
Have previously had genetic counseling regarding their FMR1 status.
EXCLUSION CRITERIA:
History of infertility or infertility in a first degree relative.
Acute or chronic disease.
Menopause due to surgery, radiation, or chemotherapy.
Current use of oral contraceptives or hormone replacement therapy, or use of these agents within the previous 3 months.
Use within the previous three months of any medication known to affect the hypothalamic-pituitary-ovarian axis (including over-the-counter and alternative medicines).
History of excessive exercise (greater than 10 hours a week).
Girls will be excluded because there are no data regarding FSH use in children.
Smokers.
Pregnant.
Breast feeding.
Persistent ovarian masses.
History of tumors of the ovary, breast, uterus, hypothalamus, or pituitary.
History of breast or endometrial cancer.
History of hypersensitivity to recombinant FSH or any one of its excipients.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Control
Control for FSH stimulation test
|
No injection of FSH
|
|
Experimental: Drug: FSH
FSH Stimulation Test
|
FSH Stimulation Test
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels.
Prazo: 24 hours
|
24 hours
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Follicle Stimulating Hormone Stimulated Serum Estradiol (E2) Levels
Prazo: 24 hours
|
24 hours
|
Colaboradores e Investigadores
Publicações e links úteis
Publicações Gerais
- Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986 Apr;67(4):604-6.
- Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1998 Jan;91(1):12-5. doi: 10.1016/s0029-7844(97)00583-8.
- Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod. 1996 Jul;11(7):1484-6. doi: 10.1093/oxfordjournals.humrep.a019422.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 000189
- 00-CH-0189
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .